Buch, Englisch, 374 Seiten, Previously published in hardcover, Format (B × H): 178 mm x 254 mm, Gewicht: 671 g
Buch, Englisch, 374 Seiten, Previously published in hardcover, Format (B × H): 178 mm x 254 mm, Gewicht: 671 g
Reihe: Cancer Drug Discovery and Development
ISBN: 978-1-61737-401-2
Verlag: Humana Press
An in depth review of our latest understanding of the molecular events that regulate cell death and those molecules that provide targets for developing agonists or antagonists to modulate death signaling for therapeutic purposes. The authors focus on the extrinsic system of death receptors, their regulation and function, and their abnormalities in cancer. Topics of particular interest include resistance to apoptosis, TRAIL signaling, death receptors in embryonic development, mechanisms of caspase activation, and death receptor mutations in cancer. Additional chapters address death signaling in melanoma, synthetic retinoids and death receptors, the role of p53 in death receptor regulation, immune suppression of cancer, and combination therapy with death ligands.
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Mammalian Cell Death Pathways.- Resistance to Apoptosis in Cancer Therapy.- Structures of TNF Receptors and Their Interactions With Ligands.- Death Receptor Signaling in Embryonic Ectodermal Development.- Adaptor Proteins in Death Receptor Signaling.- Caspase Activation by the Extrinsic Pathway.- Death Signaling and Therapeutic Applications of TRAIL.- Death Receptor Mutations.- Regulation of Death Receptors.- Regulation of Trail Receptor Expression in Human Melanoma.- Regulation of Death Receptors by Synthetic Retinoids.- Role of p53 in Regulation of Death Receptors.- Proapoptotic Gene Silencing Via Methylation in Human Tumors.- Regulation of Death Receptor-Induced Apoptosis by NF-?B and Interferon Signaling Pathways.- TRAIL in Cancer Therapy.- Expression and Regulation of Death Receptors in Multiple Myeloma and Prostate Carcinoma.- Regulation of TRAIL-Induced Apoptosis by Transcriptional Factors.- Sensitizing Tumor Cells by Targeting Death Receptor Signaling Inhibitors.- Ceramide, Ceramidase, and FasL Gene Therapy in Prostate Cancer.- Gene Therapy Targeting Receptor-Mediated Cell Death to Cancers.- Combination of Chemotherapy and Death Ligands in Cancer Therapy.
